Rebecca L Thomas1, Frank D Dunstan2, Stephen D Luzio1, Sharmistha Roy Chowdhury3, Rachel V North4, Sarah L Hale5, Robert L Gibbins6, David R Owens1. 1. Diabetes Research Group, Swansea University, Swansea, Wales, UK. 2. Institute of Primary Care and Public Health, Cardiff University, Cardiff, Wales, UK. 3. Institute of Molecular and Experimental Medicine, Cardiff University, Cardiff, Wales, UK. 4. School of Optometry & Vision Sciences, Cardiff University, Cardiff, Wales, UK. 5. Department of Ophthalmology, Cardiff and Vale University Health Board, Cardiff, Wales, UK. 6. Retired GP, Powys, Wales, UK.
Abstract
AIMS: Determine the prevalence and severity of diabetic retinopathy (DR) and risk factors in a large community based screening programme, in order to accurately estimate the future burden of this specific and debilitating complication of diabetes. METHODS: A cross-sectional analysis of 91,393 persons with diabetes, 5003 type 1 diabetes and 86,390 type 2 diabetes, at their first screening by the community based National Diabetic Retinopathy Screening Service for Wales from 2005 to 2009. Image capture used 2×45° digital images per eye following mydriasis, classified by qualified retinal graders with final grading based on the worst eye. RESULTS: The prevalence of any DR and sight-threatening DR in those with type 1 diabetes was 56.0% and 11.2%, respectively, and in type 2 diabetes was 30.3% and 2.9%, respectively. The presence of DR, non-sight-threatening and sight-threatening, was strongly associated with increasing duration of diabetes for either type 1 or type 2 diabetes and also associated with insulin therapy in those with type 2 diabetes. CONCLUSIONS: Prevalence of DR within the largest reported community-based, quality assured, DR screening programme, was higher in persons with type 1 diabetes; however, the major burden is represented by type 2 diabetes which is 94% of the screened population. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: Determine the prevalence and severity of diabetic retinopathy (DR) and risk factors in a large community based screening programme, in order to accurately estimate the future burden of this specific and debilitating complication of diabetes. METHODS: A cross-sectional analysis of 91,393 persons with diabetes, 5003 type 1 diabetes and 86,390 type 2 diabetes, at their first screening by the community based National Diabetic Retinopathy Screening Service for Wales from 2005 to 2009. Image capture used 2×45° digital images per eye following mydriasis, classified by qualified retinal graders with final grading based on the worst eye. RESULTS: The prevalence of any DR and sight-threatening DR in those with type 1 diabetes was 56.0% and 11.2%, respectively, and in type 2 diabetes was 30.3% and 2.9%, respectively. The presence of DR, non-sight-threatening and sight-threatening, was strongly associated with increasing duration of diabetes for either type 1 or type 2 diabetes and also associated with insulin therapy in those with type 2 diabetes. CONCLUSIONS: Prevalence of DR within the largest reported community-based, quality assured, DR screening programme, was higher in persons with type 1 diabetes; however, the major burden is represented by type 2 diabetes which is 94% of the screened population. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Einas S Elwali; Ahmed O Almobarak; Mona A Hassan; Amir A Mahmooud; Heitham Awadalla; Mohamed H Ahmed Journal: Int J Ophthalmol Date: 2017-06-18 Impact factor: 1.779
Authors: Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank Journal: Cochrane Database Syst Rev Date: 2015-01-31
Authors: Sophia Y Wang; Chris A Andrews; Thomas W Gardner; Michael Wood; Kanakadurga Singer; Joshua D Stein Journal: JAMA Ophthalmol Date: 2017-05-01 Impact factor: 7.389
Authors: Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski Journal: Rev Diabet Stud Date: 2015-08-10